

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2024/249954 A9

(43) International Publication Date
05 December 2024 (05.12.2024)

WIPO | PCT

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 47/18 (2017.01)
A61K 9/127 (2006.01) A61K 47/69 (2017.01)
A61K 31/7105 (2006.01) C12N 15/88 (2006.01)

(21) International Application Number:

PCT/US2024/032141

(22) International Filing Date:

31 May 2024 (31.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/505,424	31 May 2023 (31.05.2023)	US
63/510,061	23 June 2023 (23.06.2023)	US
63/520,303	17 August 2023 (17.08.2023)	US
63/595,201	01 November 2023 (01.11.2023)	US

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))

(48) Date of publication of this corrected version:

03 April 2025 (03.04.2025)

(71) Applicant: CAPSTAN THERAPEUTICS, INC.
[US/US]; 9880 Campus Point Drive, Suite 220, San Diego, CA 92121 (US).

(72) Inventors; and

(71) Applicants: KARMALI, Priya Prakash [US/US]; 11438 Cypress Canyon Park Drive, San Diego, CA 92131 (US). TANIS, Steven [US/US]; 1750 Oriole Ct., Carlsbad, CA 92011 (US). BAO, Yanjie [US/US]; 10749 Cherry Hill Drive, San Diego, CA 92130 (US).

(74) Agent: TA, My Chau; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(15) Information about Correction:

see Notice of 03 April 2025 (03.04.2025)

(54) Title: LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONS

(57) Abstract: Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.



WO 2024/249954 A9